In a new job - March 4, 2019
Britt Meelby Jensen is the new CEO of Atos Medical
Britt Meelby Jensen has been appointed CEO of the Swedish medtech company Atos Medical. As previously reported, Britt Meelby Jensen, has left her position as CEO of Zealand Pharma, and now, it is official that she is the new CEO of Atos Medical. The medtech company is based in Malmö, Sweden, and is focused on laryngectomy […]
In a new job - January 25, 2019
Mats Blom leaves Zealand Pharma
After nine years at the company, Mats Blom, Chief Financial Officer, will leave Zealand Pharma at the end of March 2019. Following the resignation of Britt Meelby Jensen on 26 November 2018, the Board of Directors has decided that Britt will be released from her duties as President and CEO as of 28 February 2019. […]
In a new job - December 1, 2018
Britt Meelby Jensen leaves Zealand Pharma
The Danish company announces that Britt Meelby Jensen has delivered her notice to resign from her position as President and CEO. Britt Meelby Jensen has accepted a CEO position in a non-competing company outside Denmark and she will remain in her position with Zealand Pharma until further notice. “I have sincerely enjoyed my four years […]
Pharma Business - August 28, 2017
Zealand Pharma to be listed on Nasdaq Denmark as well as the US
10th of August Zealand Pharma became the first Danish biotech company to be listed on Nasdaq in Denmark as well as the US. With the dual listing, Zealand Pharma will become more attractive to US investors. ”To us it is an achievement and a major milestone that we today show Zealand to be an attractive […]
Clinical Trials - June 26, 2017
Phase 2a trial results from Zealand Pharma
Zealand Pharma and Beta Bionics announce a positive outcome from the Phase 2a clinical safety trial using dasiglucagon in the dualhormone artificial pancreas system, developed at Boston University and licensed to Beta Bionics. The study was conducted at the Massachusetts General Hospital Diabetes Research Center in Boston, MA, USA. The aim of the trial was […]
Clinical Trials - June 20, 2017
Positive clinical trial result from Zealand Pharma
Zealand Pharma announces positive results from the Phase 2 trial of glepaglutide in adult patients with short bowel syndrome (SBS). Glepaglutide is a novel longacting GLP-2 analogue invented and fully owned by Zealand. The trial was initiated in 2016 at Rigshospitalet, University of Copenhagen, Denmark, and the aim was to assess the efficacy, safety and […]
